Navigation Links
Agilent Technologies and A*STAR launch all-in-one drug screening platform
Date:7/21/2011

Agilent Technologies Inc. (NYSE: A) and A*STAR's Experimental Therapeutics Centre (ETC) today announced the launch of a drug screening platform within ETC's new Singapore Screening Centre. This partnership will provide a full spectrum of state-of-the-art automation technologies to biomedical researchers, enabling highly efficient drug screening in one location.

The Singapore Screening Centre conducts high-throughput screening to identify potential drug candidates against disease, using a library of over 300,000 chemical compounds. It now employs Agilent's dual BioCel 1200 integrated system, which automates and coordinates the various processes of high-throughput screening, including compound management, assay plate preparation and experiment replication, to ensure high-quality data while saving time and reducing the possibility of human error.

"The location of Agilent's technology platform within ETC's newly set up Singapore Screening Centre will not only enhance our ability to produce proprietary drugs for Singapore, but also enable us to engage a diversity of biomedical research players from across the world," said Dr. Alex Matter, CEO of ETC. "We expect collaborations with top private sector partners such as Agilent will go a long way to accelerate the development of medical solutions."

The centerpiece of Agilent's BioCel System is a Direct Drive Robot (DDR) that provides significant advantages in speed and ease of use with its one-touch teaching and innovative design. The BioCel system is also customised specifically to ETC's requirements, linking the instruments to ETC's laboratory information management system so that the BioCel database and sample inventory are synchronised and up to date.

The new platform will boost ongoing drug discovery projects at the Singapore Screening Center, including a collaboration with Duke University and the National University of Singapore Graduate Medical School to screen for novel gastric cancer medicines; and another with DSO National Laboratories and A*STAR's Genome Institute of Singapore to discover anti-bacterial drugs using a novel whole animal-screening platform.

"ETC is a leading research institution in Singapore and we look forward to working closely with them to collectively drive drug discovery research," said Yvonne Linney, vice president and general manager, Agilent Automation Solutions Group. "We continue to see growth and opportunities for automated solutions in both Asia and the pharmaceutical markets as a whole."

Singapore has built up strong scientific foundations and capabilities in translational and clinical research to support industry efforts to accelerate the drug discovery process with next-generation technologies. Today, leading pharmaceutical, biotechnology and medical technology companies have invested in more than 50 commercial-scale facilities in Singapore. In 2009, Agilent opened a life sciences manufacturing facility in its Yishun, Singapore campus. The facility expanded Agilent's presence in the region and brought it closer to its Asia Pacific customer base.


'/>"/>

Contact: Adela Foo
adela_foo@a-star.edu.sg
656-826-6218
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

Related biology news :

1. Agilent Technologies Expands Agreement to Offer AMDeC Members Preferential Pricing on Products Through AMDeC F.I.R.S.T.™ Vendor Partnership Program
2. Ambry Genetics Announces Certified Service Provider Status for Agilent Microarrays
3. Laser, electric fields combined for new lab-on-chip technologies
4. Iowa State hybrid lab combines technologies to make biorenewable fuels and products
5. Reportlinker Adds Biometrics: Technologies and Global Markets
6. How natures best ideas inspire innovative new technologies
7. Young Caltech engineers recognized for innovative work in disease diagnostic technologies
8. Nottingham success in green technologies awards
9. From Disruptive to Productive: Unisys Predicts 2011 to be Year of Practical Application of Cutting-Edge Technologies
10. Reportlinker Adds Biometrics: Technologies and Global Markets
11. The CLEAR Program is Back and Oberthur Technologies Remains a Key Partner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... and solutions to the healthcare market. The company's primary focus is on new ... and marketing strategies that are necessary to help companies efficiently bring their products ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
Breaking Biology Technology: